PBYI Q2 2023 Earnings — Puma Biotechnology, Inc. Revenue & Financial Results | Market Cap Arena

PBYIPuma Biotechnology, Inc.

$311M

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$55M-8.3% YoY

Gross Profit

$43M78.3% margin

Operating Income

$5M9.0% margin

Net Income

$2M3.9% margin

EPS (Diluted)

$0.04

QoQ Revenue Growth

+3.4%

Cash Flow

Operating Cash Flow

$3M

Free Cash Flow

$3M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$200M

Total Liabilities

$170M

Stockholders' Equity

$30M

Cash & Equivalents

$60M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$55M	$60M	-8.3%
Gross Profit	$43M	$45M	-4.2%
Operating Income	$5M	$12M	-59.4%
Net Income	$2M	$9M	-77.3%

Revenue Segments

Product

$52M94%

Royalty

$3M6%